Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 6kWORD 24k
2 July 2015
E-010667-15
Question for written answer E-010667-15
to the Commission
Rule 130
Dominique Bilde (ENF) , Marie-Christine Arnautu (ENF) , Marine Le Pen (ENF) , Dominique Martin (ENF) , Mylène Troszczynski (ENF) , Sylvie Goddyn (ENF) , Sophie Montel (ENF) , Florian Philippot (ENF) , Steeve Briois (ENF) , Marie-Christine Boutonnet (ENF) , Philippe Loiseau (ENF) , Edouard Ferrand (ENF) , Bruno Gollnisch (NI) , Gilles Lebreton (ENF) , Nicolas Bay (ENF) , Aymeric Chauprade (ENF) , Jean-François Jalkh (ENF) , Bernard Monot (ENF) , Louis Aliot (ENF) , Jean-Marie Le Pen (NI)

 Subject:  Fight against breast cancer in Europe
 Answer in writing 

Each year, over 380 000 women in Europe are affected by some form of metastatic cancer and in 2012 alone breast cancer claimed the lives of almost 92 000 women in the European Union. The European Parliament has been repeatedly calling for the introduction of mammographic screening programmes.

However, a number of experts question the advisability of this on the grounds that it could, in certain cases, lead to over-diagnosis.

1.What view does the Commission take of the various scientific studies warning of over-diagnosis and the related risks of mammographic screening?

2.What steps will the Commission take to combat breast cancer effectively?

Original language of question: FR 
Legal notice - Privacy policy